ReviewDrug design, development and therapy2019
Caplacizumab as an emerging treatment option for acquired thrombotic thrombocytopenic purpura.
Review in Drug design, development and therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 48 citations in OpenAlex.
- Effectiveness of caplacizumab in the first-line treatment for acquired thrombotic thrombocytopenic purpura: single center experience.Therapeutic advances in hematology · 2026Article
- Integrative and Emerging Models in Antibody Research: A Comprehensive Review.Antibody therapeutics · 2025Review
- Development of a potent neutralizing nanobody against canine distemper virus hemagglutinin protein.Frontiers in immunology · 2025Article
- Co-crystallisation and humanisation of an anti-HER2 single-domain antibody as a theranostic tool.PloS one · 2023Article
- An Engineered IgG-VHH Bispecific Antibody against SARS-CoV-2 and Its Variants.Small methods · 2022Article
- Development of therapeutic antibodies for the treatment of diseases.Molecular biomedicine · 2022Review
- Diagnosis and treatment of thrombotic microangiopathy.International journal of laboratory hematology · 2022Review
- COVID-19 associated coagulopathy: Mechanisms and host-directed treatment.The American journal of the medical sciences · 2022Review
- A novel nanobody-heavy chain antibody against Angiopoietin-like protein 3 reduces plasma lipids and relieves nonalcoholic fatty liver disease.Journal of nanobiotechnology · 2022Article
- Structure-Based Cyclic Glycoprotein Ibα-Derived Peptides Interfering with von Willebrand Factor-Binding, Affecting Platelet Aggregation under Shear.International journal of molecular sciences · 2022Article
- Generation of TIM3 inhibitory single-domain antibodies to boost the antitumor activity of chimeric antigen receptor T cells.Oncology letters · 2021Article
- Development of multivalent nanobodies blocking SARS-CoV-2 infection by targeting RBD of spike protein.Journal of nanobiotechnology · 2021Article
- Case Report: Two Cases of Pediatric Thrombotic Thrombocytopenic Purpura Treated With Combined Therapy.Frontiers in pediatrics · 2021Article
- Identification and in vivo characterization of a brain-penetrating nanobody.Fluids and barriers of the CNS · 2020Article
- A C3-specific nanobody that blocks all three activation pathways in the human and murine complement system.The Journal of biological chemistry · 2020Article
- Diagnostic and therapeutic potential of shark variable new antigen receptor (VNAR) single domain antibody.International journal of biological macromolecules · 2020Review
- G Protein-Coupled Receptors in Asthma Therapy: Pharmacology and Drug Action.Pharmacological reviews · 2020Review
- Assessment and Monitoring of Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura (iTTP): Strategies to Improve Outcomes.Journal of blood medicine · 2020Review
- Isolation of rabbit single domain antibodies to B7-H3 via protein immunization and phage display.Antibody therapeutics · 2020Article
- Longitudinal assessments of plasma ADAMTS13 biomarkers predict recurrence of immune thrombotic thrombocytopenic purpura.Blood advances · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thrombotic thrombocytopenic purpura (TTP) is a rare disease with a mortality rate of over 90% if left untreated. Therapeutic plasma exchange (PEX) is the mainstay of treatment of acquired TTP (aTTP), and with the introduction of PEX, the mortality rate declined dramatically below 20%. Although PEX together with corticosteroids are the backbone of the upfront management of patients with aTTP with successful outcomes, patients may remain refractory and/or relapse following an initial response to this treatment. There are some therapeutic options, which can be used among these patients, helping in improving outcomes of aTTP. Caplacizumab (formerly ALX-0081 or ALX-0681) is a humanized single-variable domain immunoglobulin that recognizes the human von Willebrand factor (vWF) A1 domain and inhibits the vWF-platelet glycoprotein 1b-alpha (GP1b-α) interaction. The drug was first developed for the prevention of thrombosis in high-risk patients with acute coronary syndrome undergoing percutaneous coronary intervention; however, drug development for this indication has been discontinued. Recently, caplacizumab received its first approval following Phase II TITAN and Phase III HERCULES trials in the European Union (EU) for the treatment of acute episode of aTTP in adult patients, in addition to PEX and immunosuppression. This review focuses on the use of caplacizumab as an emerging treatment option in patients with aTTP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.